Zentalis Pharmaceuticals, Inc. (ZNTL) Reports Interim OS Signal in DENALI Part 1b

Zentalis reported interim overall survival data from DENALI Part 1b in platinum—resistant ovarian cancer, with the abstract stating Cyclin E1 is a highly selective predictive biomarker and OS compares favorably to historical chemo in Cyclin E1—positive patients.Material DetailsContext by AI Analyst…